HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Press Releases Hansoh Pharmaceutical Group Company Limited

Stocks

3692

KYG549581067

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 09:08:13 09/06/2026 BST			5-day change	1st Jan Change
28.56 ^HKD	-0.76%		-8.29%	-20.84%

11:57am	Weight-loss drug developers line up to tap lucrative market as competition heats up	RE
06-07	Hansoh Pharmaceutical Group Company Limited(SEHK:3692) added to Hang Seng China Enterprises Index	CI

Press Releases

05-15	Hansoh Pharmaceutical : SID 2026 \| HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-20118 IN HEALTHY ADULTS AND PSORIASIS PATIENTS	PU
04-28	Hansoh Pharmaceutical : ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025	PU
04-22	Hansoh Pharmaceutical : AACR 2026 \| HANSOH PHARMA PRESENTED RESULTS OF HS-10504 (A NOVEL, POTENT, HIGHLY SELECTIVE, FOURTH-GENERATION EGFR TKI) FROM A FIRST IN HUMAN PHASE 1 STUDY IN PATIENTS WITH ADVANCED NSCLC	PU
04-20	Hansoh Pharmaceutical : AACR 2026 \| HANSOH PHARMA PRESENTED PHASE 1 RESULTS OF RISVUTATUG REZETECAN PLUS ADEBRELIMAB IN NON-SQUAMOUS NSCLC WITHOUT ACTIONABLE GENOMIC ALTERATIONS	PU
04-17	Hansoh Pharmaceutical : AAN 2026 \| HANSOH PHARMA PRESENTED PHASE 1B/2 DATA OF HS-10506 (A SELECTIVE OREXIN-2 RECEPTOR ANTAGONIST) IN INSOMNIA	PU
04-03	Hansoh Pharmaceutical : PHARMA – XINYUE’S THIRD INDICATION APPROVED FOR MARKETING FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN ADULT PATIENTS	PU
03-28	Hansoh Pharmaceutical : WCN 2026 \| HANSOH PHARMA PRESENTED PHASE 1 DATA OF HS-10542（A COMPLEMENT FACTOR B INHIBITOR）IN HEALTHY PARTICIPANTS	PU
03-27	Hansoh Pharmaceutical : ELCC 2026 \| HANSOH PHARMA PRESENTED RESULTS OF DALMELITINIB (HS-10241, A HIGHLY SELECTIVE MET-TKI) COMBINED WITH AUMOLERTINIB FROM A PHASE IB STUDY IN PATIENTS WITH MET-AMPLIFIED ADVANCED NSCLC POST EGFR TKI	PU
03-07	Hansoh Pharmaceutical : OLATOREPATIDE (HS-20094) ACHIEVES UP TO 19.3% WEIGHT LOSS AT WEEK 48 IN PHASE 3 STUDY WITH FAVORABLE GASTROINTESTINAL TOLERABILITY	PU
03-06	Hansoh Pharmaceutical : CANCER CELL PUBLISHES PHASE 1 LUNG CANCER RESULTS OF RISVUTATUG REZETECAN	PU
02-28	Hansoh Pharmaceutical : ASCO GU 2026 \| HANSOH PHARMA PRESENTED PHASE 2 DATA OF RISVUTATUG REZETECAN IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER	PU
02-28	Hansoh Pharmaceutical : ESGO 2026 \| HANSOH PHARMA PRESENTED DATA FOR MOCERTATUG REZETECAN (HS-20089,A B7-H4-TARGETED ADC) IN PATIENTS WITH PLATINUM-SENSITIVE OVARIAN CANCER,WITH ONE STUDY SELECTED AS LBA	PU
02-26	Hansoh Pharmaceutical : PHARMA ANNOUNCES THE NEW DRUG APPLICATION OF DALMELITINIB MESYLATE TABLETS WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION	PU
01-12	Hansoh Pharmaceutical : PHARMA \| AMEILE’S FIFTH INDICATION FOR “TARGETED THERAPY PLUS CHEMOTHERAPY” APPROVED, MARKING FULL-COURSE COVERAGE OF CHINA’S ORIGINAL THIRD-GENERATION EGFR-TKI	PU
12-16	Hansoh Pharmaceutical : PHARMA GRANTS GLENMARK EXCLUSIVE MULTI-REGIONAL RIGHTS REGARDING AUMOLERTINIB	PU
12-11	Hansoh Pharmaceutical : ESMO ASIA \| HANSOH PHARMA ANNOUNCES RESULTS OF RESENCATINIB (HS-10365，A HIGHLY SELECTIVE RET INHIBITOR）FOR THE TREATMENT OF PATIENTS WITH RET-FUSION LOCALLY ADVANCED OR METASTATIC NSCLC	PU
12-10	Hansoh Pharmaceutical : ESMO ASIA \| HANSOH PHARMA ANNOUNCES MINI ORAL PRESENTATION OF PHASE 1 STUDY OF RISVUTATUG REZETECAN (HS-20093, A B7-H3-TARGETED ADC) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)	PU
12-08	HANSOH PHARMA: TWO NEW INDICATIONS OF ALMONERTINIB ADDED TO THE 2025 NRDL; MULTIPLE INNOVATIVE DRUGS RENEWED	PU
11-10	Hansoh Pharmaceutical : PHARMA ANNOUNCES ORAL PRESENTATION OF PHASE 2 STUDY FINDINGS OF HS-20089 (B7-H4 ADC) IN PLATINUM-RESISTANT OVARIAN CANCER AT IGCS 2025	PU
23/10/25	Hansoh Pharmaceutical : CHINA NMPA ACCEPTS NEW DRUG APPLICATION FOR HS-10365 CAPSULES FOR THE TREATMENT OF RET FUSION-POSITIVE NSCLC	PU
20/10/25	Hansoh Pharmaceutical : ESMO 2025 \| Hansoh Pharma Announces Proffered Paper Presentation of Phase 2 Study on HS-20093 (B7-H3-targeted ADC) in Relapsed or Refractory Sarcomas	PU
20/10/25	Hansoh Pharmaceutical : ESMO 2025 \| Hansoh Pharma Presents the phase 2 study findings of HS-20089 (B7-H4-targeted ADC), in patients with platinum-resistant ovarian cancer (PROC)	PU
17/10/25	Hansoh Pharmaceutical : GRANTS ROCHE AN EXCLUSIVE LICENSE TO NOVEL CDH17-TARGETING ADC HS-20110	PU
01/09/25	Hansoh Pharmaceutical : 翰森制药 \| 昕越®第二项适应症获批上市，适用于免疫球蛋白G4相关性疾病成人患者	PU
05/06/25	Hansoh Pharma \| Aumolertinib: Approved by UK’s MHRA for the Treatment of NSCLC — Marking the First Overseas Launch of China-Developed EGFR-TKI	PU